The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp396
APPLYING MACHINE LEARNING TO BIOLOGICAL DATA FOR PRECISION THERAPY IN IBD
Date
May 7, 2023
Explore related products in the following collection:
Over the past decade, big data and artificial intelligence (AI) have become standard concepts in digestive disease research, both as individual tools and applied together. Artificial intelligence algorithms and large datasets are now applied to everything from unraveling the pathophysiology of disease mechanisms in model systems to precisely selecting the most appropriate treatment courses for patients. Speakers in this session will provide examples where big data and artificial intelligence have successfully advanced science and patient care, where these tools have failed to live up to expectations, and provide perspective on overcoming obstacles to further developing the tools. The session will focus on three thematic areas where AI and big data impact GI: clinical databases and natural language processing, biological datasets, and imaging.
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…